Forecast

Buy	13
Hold	1
Sell	0

News Go to news feed

SCYNEXIS expands focus to rare diseases and plans phase II for ADPKD drug SCY-770

At the Cantor Fitzgerald Healthcare Conference, SCYNEXIS presented its repositioning as a company for orphan indications, with two programs: an antifungal and the AMPK activator SCY-770 for ADPKD. SCY-770 is supported by extensive preclinical and early human data; however, proof of efficacy in ADPKD is still pending. Near-term catalysts are the completion of two phase I studies this quarter and the planned start of a phase II study by the end of 2024, with interim data expected in the second half of 2025. Management says cash runway is sufficient to reach the next milestones and highlights long-term patent protection and potential orphan exclusivity. » More on de.investing.com
Sanjay Subramanian to become CFO at SCYNEXIS

SCYNEXIS has appointed Sanjay Subramanian as its new chief financial officer effective Tuesday. He replaces Ivor Macleod, who is resigning after nearly four years and will remain to support the transition through Oct. 9. Subramanian brings more than 20 years of experience in finance, capital markets and business development in the biotech and pharmaceutical sectors, most recently serving as CFO and head of business development at Inozyme Pharma. Upon appointment he received an option on 100,000 common shares at an exercise price of USD 4.91 per share, with a four-year vesting period and a ten-year term. SCYNEXIS is developing, among other assets in the clinical phase, SCY-770 for autosomal-dominant polycystic kidney disease and an antifungal platform. » More on de.investing.com
SCYNEXIS reports earnings per share of $0.63 despite sharp revenue decline

For the quarter ended 30 June 2026, SCYNEXIS reported earnings of $0.63 per share, after -$1.12 in the prior year. Revenue fell 83.09 percent to $0.2 million (prior year: $1.4 million). » More on finanzen.net

Financials

In the last quarter, Scynexis had revenue of €205.91k and net profit of €6.48m

(EUR)	June 2026	YoY
Revenue	205.91k	82.21%
Gross profit	205.91k	82.21%
Net profit	6.48m	210.96%
EBITDA	6.48m	210.96%

Fundamentals

Metric	Value
Market capitalization	€26.38m
Number of shares	6.29m
52-week high/low	€8.25 - €3.06
Dividends	No
Beta	1.11
P/E ratio	-2.63
PEG ratio	0.01
P/B ratio	0.86
P/S ratio	1.58

Company profile

SCYNEXIS, Inc. ist ein Biotechnologieunternehmen, das Produkte zur Behandlung von Pilzinfektionen in den Vereinigten Staaten entwickelt. Es bietet BREXAFEMME (Ibrexafungerp-Tabletten) für die Behandlung der vulvovaginalen Candidose (VVC) an. Das Unternehmen entwickelt seinen führenden Produktkandidaten, Ibrexafungerp, als neuartiges orales und intravenöses Medikament zur Behandlung verschiedener Pilzinfektionen, einschließlich rezidivierender VVC, invasiver Aspergillose, invasiver Candidose und refraktärer invasiver Pilzinfektionen; und ibrexafungerp, das die Phase-3-CANDLE-Studie zur Prävention rezidivierender VVC abgeschlossen hat. Es unterhält Forschungskooperationen mit Merck Sharp & Dohme Corp, Hansoh (Shanghai) Health Technology Co., Ltd, Jiangsu Hansoh Pharmaceutical Group Company Limited und R-Pharm, CJSC zur Entwicklung und Vermarktung von ibrexafungerp. Das Unternehmen war früher als SCYNEXIS Chemistry & Automation, Inc. bekannt und änderte im Juni 2002 seinen Namen in SCYNEXIS, Inc. SCYNEXIS, Inc. wurde 1999 gegründet und hat seinen Hauptsitz in Jersey City, New Jersey.